|
|
||||||||
|
|
|||||||||
|
|
Radiopharmaceutical Chemistry: New Chemistry-OtherNew Chemistry-Other Posters |
1 Molecular Imaging Branch, NIMH/NIH, Bethesda, Maryland
1284
Objectives: Due to a largely unfulfilled need for simple methods to introduce fluorine-18 into an electron-rich aryl ring present in many radiotracers for PET imaging, diaryliodonium salts are gaining interest as precursors for fluorination with 18F-. Also there is growing interest in the potential advantages of miniaturizing 18F-radiochemistry reactors and apparatus. Here we used the reaction of 18F- with diphenyliodonium tosylate as a model to demonstrate the feasibility and efficiency of using a microfluidic device for such reactions.
Methods: Cyclotron-produced 18F- in H218O was trapped on a QMA cartridge and then released into a solution of K2CO3 (0.8 mg) and K2.2.2 (4.5 mg) in MeCN-H2O (9: 1 v/v; 150 µL). Water was removed by two azeotropic evaporations with MeCN. The resulting 18F--K2.2.2-K+ complex (0.1–1 mCi/10 µL) and diphenyliodonium tosylate (40 µg/10 µL), both in MeCN, were delivered from two separate storage loops (each 255 µL) to either a 2 or 4 m coiled tube micro-reactor. The reaction mixture was quenched with MeCN-H2O (1: 1 v/v, 1 mL). The radical scavenger TEMPO was added to some reactions. Amounts of precursor, temperature and flow rates were varied. Decay-corrected radiochemical yields (RCYs) of [18F]fluorobenzene were measured with radio-HPLC.
Results: The RCYs of [18F]fluorobenzene ranged from 7 to 81% with TEMPO and from 2 to 40% without TEMPO. A small amount of precursor (40 or 80 µg) sufficed for each of ten different reactions. Reaction times were between 50 and 190 s. Overall processing times were between 3 and 8 min, depending on reactor length and reagent flow rates.
Conclusions: The micro-fluidic device proved very effective for rapidly optimizing the conditions of the radiofluorination reaction and was efficient in producing high RCYs of [18F]fluorobenzene from small amounts of precursor in short times.
Research Support: IRP, NIMH, NIH
| ||||||||||||||||||||||||||||||||||||||